JP2015508102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508102A5 JP2015508102A5 JP2014558836A JP2014558836A JP2015508102A5 JP 2015508102 A5 JP2015508102 A5 JP 2015508102A5 JP 2014558836 A JP2014558836 A JP 2014558836A JP 2014558836 A JP2014558836 A JP 2014558836A JP 2015508102 A5 JP2015508102 A5 JP 2015508102A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- hydrogen
- pharmaceutically acceptable
- acceptable salt
- calcification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 208000004434 Calcinosis Diseases 0.000 claims 8
- 230000002308 calcification Effects 0.000 claims 8
- 208000005475 Vascular calcification Diseases 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004476 heterocycloamino group Chemical group 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims 2
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000033173 Generalized arterial calcification of infancy Diseases 0.000 claims 1
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000003397 Keutel syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000004900 arterial calcification of infancy Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 210000001715 carotid artery Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 210000004177 elastic tissue Anatomy 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003235 pyrrolidines Chemical class 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- -1 tautomer Substances 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601957P | 2012-02-22 | 2012-02-22 | |
| US61/601,957 | 2012-02-22 | ||
| PCT/US2013/027191 WO2013126608A1 (en) | 2012-02-22 | 2013-02-21 | Sulfonamide compounds and uses as tnap inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018002991A Division JP6544545B2 (ja) | 2012-02-22 | 2018-01-11 | Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508102A JP2015508102A (ja) | 2015-03-16 |
| JP2015508102A5 true JP2015508102A5 (enExample) | 2016-03-24 |
| JP6302846B2 JP6302846B2 (ja) | 2018-03-28 |
Family
ID=49006214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558836A Active JP6302846B2 (ja) | 2012-02-22 | 2013-02-21 | Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用 |
| JP2018002991A Active JP6544545B2 (ja) | 2012-02-22 | 2018-01-11 | Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018002991A Active JP6544545B2 (ja) | 2012-02-22 | 2018-01-11 | Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9458147B2 (enExample) |
| EP (1) | EP2817292B1 (enExample) |
| JP (2) | JP6302846B2 (enExample) |
| KR (1) | KR102083041B1 (enExample) |
| CN (1) | CN104334527B (enExample) |
| AU (1) | AU2013222345B2 (enExample) |
| BR (1) | BR112014020773A2 (enExample) |
| CA (1) | CA2865071C (enExample) |
| RU (1) | RU2627701C2 (enExample) |
| WO (1) | WO2013126608A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5986570B2 (ja) | 2010-09-01 | 2016-09-06 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 筋修復および再生のための組成物および方法 |
| BR112014020773A2 (pt) | 2012-02-22 | 2020-10-27 | Sanford-Burnham Medical Research Institute | compostos de sulfonamida e seus usos como inibidores tnap |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| CN103755628B (zh) * | 2014-01-27 | 2015-07-29 | 河北科技大学 | 2-氨基-3-碘-5-溴吡啶的合成方法 |
| WO2016054056A1 (en) * | 2014-10-01 | 2016-04-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating pxe with tnap inhibitors |
| CN107207527B (zh) | 2015-07-08 | 2019-10-01 | 第一三共株式会社 | 作为tnap抑制剂的吡啶并噁嗪酮化合物 |
| ITUA20161994A1 (it) * | 2016-03-24 | 2017-09-24 | Azienda Ospedaliera Univ Senese | Uso degli inibitori ddx3 come agenti anti-iperproliferativi |
| MY200642A (en) * | 2016-06-08 | 2024-01-08 | Clementia Pharmaceuticals Inc | Method for treating heterotopic ossification |
| TW201829417A (zh) | 2016-12-23 | 2018-08-16 | 日商第一三共股份有限公司 | 氧氮呯化合物 |
| EP3559007B1 (en) * | 2016-12-23 | 2023-08-16 | Daiichi Sankyo Company, Limited | Sulfonamide compounds having tnap inhibitory activity |
| WO2020014330A1 (en) * | 2018-07-10 | 2020-01-16 | Academia Sinica | A biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis |
| KR102880470B1 (ko) | 2018-10-23 | 2025-11-03 | 다이이찌 산쿄 가부시키가이샤 | 바이아릴 유도체 |
| AU2020239048B2 (en) | 2019-03-12 | 2025-10-16 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| KR20210144821A (ko) | 2019-03-29 | 2021-11-30 | 아르커스 바이오사이언시즈 인코포레이티드 | 규명된 아데노신 지문을 이용한 암의 치료방법 |
| WO2021113512A1 (en) | 2019-12-04 | 2021-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing blood-brain barrier drug transport by targeting endogenous regulators |
| CN113683563B (zh) * | 2021-08-31 | 2024-01-30 | 合肥工业大学 | 一种多取代3-磺酰胺喹啉化合物的合成方法 |
| CN115837023B (zh) * | 2023-02-20 | 2023-05-16 | 中山大学附属第八医院（深圳福田） | 1-甲基烟酰胺在制备抗血管钙化药物中的应用 |
| KR102790313B1 (ko) * | 2023-11-07 | 2025-04-04 | 주식회사 레드엔비아 | Tnap 저해 화합물 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| ES2341843T3 (es) * | 2000-02-03 | 2010-06-29 | EISAI R&D MANAGEMENT CO., LTD. | Inhibidores de la expresion de integrina. |
| CA2468745A1 (en) * | 2001-11-30 | 2003-06-12 | The Burnham Institute | Induction of apoptosis in cancer cells |
| GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| US20040110802A1 (en) * | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| AU2003265382A1 (en) * | 2002-08-23 | 2004-03-11 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
| ATE363470T1 (de) | 2002-11-18 | 2007-06-15 | Chemocentryx Inc | Arylsulfonamide |
| CN100589803C (zh) * | 2004-07-28 | 2010-02-17 | 霍夫曼-拉罗奇有限公司 | 芳基-吡啶衍生物 |
| US20090142347A1 (en) * | 2004-09-29 | 2009-06-04 | The Burnham Institute For Medical Research | Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| GB0425026D0 (en) * | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
| JP2008519814A (ja) * | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| PT1860941E (pt) * | 2005-03-16 | 2008-12-22 | Basf Se | Bifenil-n-(4-piridil)metilsulfonamidas |
| WO2007014008A2 (en) * | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| KR20080104310A (ko) * | 2006-02-14 | 2008-12-02 | 바스프 에스이 | 해충 방제를 위한 피리딘-4-일메틸아미드 |
| CN101484438A (zh) * | 2006-05-03 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 吡唑衍生物及其作为p13k抑制剂的用途 |
| EP2016075A1 (en) * | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
| AU2007293653B2 (en) * | 2006-09-08 | 2011-02-17 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| EP2433496A1 (en) * | 2007-05-08 | 2012-03-28 | Burnham Institute for Medical Research | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
| EP2190466A4 (en) * | 2007-08-10 | 2011-12-21 | Burnham Inst Medical Research | Tissue-specific alkaline phosphatase (TNAP) activators and their use |
| US8039493B2 (en) * | 2007-09-27 | 2011-10-18 | Hoffmann-La Roche Inc. | Biaryl sulfonamide derivatives |
| WO2009055418A1 (en) * | 2007-10-22 | 2009-04-30 | Smithkline Beecham Corporation | Pyridosulfonamide derivatives as pi3 kinase inhibitors |
| US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2723424A1 (en) * | 2008-05-19 | 2009-11-26 | Burnham Institute For Medical Research | Intestinal alkaline phosphatase modulators and uses thereof |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| SG175925A1 (en) * | 2009-05-15 | 2011-12-29 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| CA2944788C (en) * | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| BR112014020773A2 (pt) | 2012-02-22 | 2020-10-27 | Sanford-Burnham Medical Research Institute | compostos de sulfonamida e seus usos como inibidores tnap |
| WO2016054056A1 (en) * | 2014-10-01 | 2016-04-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating pxe with tnap inhibitors |
-
2013
- 2013-02-21 BR BR112014020773-9A patent/BR112014020773A2/pt not_active Application Discontinuation
- 2013-02-21 KR KR1020147025901A patent/KR102083041B1/ko not_active Expired - Fee Related
- 2013-02-21 RU RU2014137402A patent/RU2627701C2/ru active
- 2013-02-21 AU AU2013222345A patent/AU2013222345B2/en active Active
- 2013-02-21 CA CA2865071A patent/CA2865071C/en active Active
- 2013-02-21 WO PCT/US2013/027191 patent/WO2013126608A1/en not_active Ceased
- 2013-02-21 EP EP13752050.8A patent/EP2817292B1/en active Active
- 2013-02-21 CN CN201380021207.0A patent/CN104334527B/zh active Active
- 2013-02-21 JP JP2014558836A patent/JP6302846B2/ja active Active
- 2013-02-21 US US14/379,475 patent/US9458147B2/en active Active
-
2016
- 2016-08-19 US US15/241,905 patent/US9884826B2/en active Active
-
2018
- 2018-01-11 JP JP2018002991A patent/JP6544545B2/ja active Active
- 2018-02-05 US US15/888,736 patent/US10370333B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508102A5 (enExample) | ||
| RU2014137402A (ru) | Сульфонамидные соединения и их применение в качестве ингибиторов tnap | |
| JP7536064B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2016108987A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| JP2017538773A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2010525023A5 (enExample) | ||
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| JP2009534398A5 (enExample) | ||
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| RU2017121588A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2015517579A5 (enExample) | ||
| EA201170714A1 (ru) | Модуляторы tgr5 и способы их применения | |
| RU2021100040A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2019531279A5 (enExample) | ||
| RU2019115784A (ru) | Ингибиторы magl | |
| JP2012510502A5 (enExample) | ||
| RU2010129541A (ru) | Карбоксил- или гидроксилзамещенные производные бензимидазола | |
| PH12014500775A1 (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| JP2017508794A5 (enExample) | ||
| RU2019115059A (ru) | Модуляторы ror-гамма | |
| RU2016112547A (ru) | Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации | |
| JP2010535706A5 (enExample) |